Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive multiple ascending doses of MER511 via SC administration assigned for their cohort on Day 1 and Day 29”In the company’s words, NCT07305818 on ClinicalTrials.gov
- Tested for
- Graves Disease
- Main trialPhase 1
- “The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.”In the company’s words, NCT07305818 on ClinicalTrials.gov
Other drugs for Graves Disease
Coming up1
- 24 Jul 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 24 Jul 2028 | NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026